Literature DB >> 25159731

Surgical treatment for intrahepatic cholangiocarcinoma in Europe: a single center experience.

Hüseyin Bektas1, Cemil Yeyrek, Moritz Kleine, Florian W R Vondran, Kai Timrott, Nora Schweitzer, Arndt Vogel, Mark D Jäger, Harald Schrem, Jürgen Klempnauer, Lampros Kousoulas.   

Abstract

Intrahepatic cholangiocarcinoma is the second most common primary liver tumor. The aim of this study was to analyze retrospectively the outcome of surgical treatment and prognostic factors. Clinical, histopathological and treatment data of 221 patients treated from 1995 to 2010 at our institution were investigated. Univariate and multivariate analysis of the patient's data was performed. Patients after R0 and R1 resection presented an overall survival of 67% and 54.5% after 1 year and 40% and 36.4% after 3 years, respectively. The survival of patients without resection of the tumor was dismal with 26% and 3.4% after 1 and 3 years, respectively. Survival after resection was not statistically different in cases with R0 versus R1 resection (P = 0.639, log rank). Univariate Cox regression revealed that higher T stages are a significant hazard for survival (P = 0.048, hazard ratio (HR): 1.211, 95% confidence interval (CI): 1.002-2.465). Patients with tumor recurrence had a significantly inferior long-term survival when compared to patients without recurrence (P < 0.001, log rank). Presence of lymph node metastasis (N1) was an independent prognostic factor for survival after resection in risk-adjusted multivariate Cox regression (P < 0.001, HR: 2.577, 95% CI: 1.742-3.813). Adjuvant chemotherapy did not improve patient survival significantly (P = 0.550, log rank). Surgical resection is still the best treatment option for intrahepatic cholangiocarcinoma regarding the patient's long-term survival. R0 and R1 resection enable both better survival rates when compared to surgical exploration without resection. T status, N status, and tumor recurrence seem to be the most important prognostic factors after resection.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma; Prognostic factors; Surgical treatment

Mesh:

Year:  2014        PMID: 25159731     DOI: 10.1002/jhbp.158

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  14 in total

Review 1.  The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics.

Authors:  Yuji Morine; Mitsuo Shimada
Journal:  J Gastroenterol       Date:  2015-04-02       Impact factor: 7.527

2.  The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis.

Authors:  Nora Schweitzer; Tim Weber; Martha M Kirstein; Mareike Fischer; Anna-Maria Kratzel; Tanja Reineke-Plaaß; Frank Lehner; Michael P Manns; Arndt Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-17       Impact factor: 4.553

3.  Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma.

Authors:  Hiroya Iida; Masaki Kaibori; Shogo Tanaka; Shigekazu Takemura; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

4.  The ABO Blood Group Impacts the Survival of Patients Undergoing Pancreatoduodenectomy for Biliary Tract Cancer.

Authors:  Shozo Mori; Taku Aoki; Kazuma Tago; Takayuki Shimizu; Nobuhiro Harada; Kyung-Hwa Park; Yuhki Sakuraoka; Takayuki Shiraki; Yukihiro Iso; Keiichi Kubota
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

5.  Hepatolithiasis: clinical series, review and current management strategy.

Authors:  Osman Nuri Dilek; Ahmet Atasever; Nihan Acar; Şebnem Karasu; Emine Özlem Gür; Oğuzhan Özşay; Hakan Çamyar; Fatma Hüsniye Dilek
Journal:  Turk J Surg       Date:  2020-12-29

6.  Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.

Authors:  Jian Feng; Bin Liang; Hang-Yu Zhang; Zhe Liu; Kai Jiang; Xiang-Qian Zhao
Journal:  World J Gastrointest Surg       Date:  2022-05-27

7.  Modified ante situm liver resection without use of cold perfusion nor veno-venous bypass for treatment of hepatic lesions infiltrating the hepatocaval confluence.

Authors:  F Oldhafer; K I Ringe; K Timrott; M Kleine; O Beetz; W Ramackers; S Cammann; J Klempnauer; F W R Vondran; H Bektas
Journal:  Langenbecks Arch Surg       Date:  2018-02-22       Impact factor: 3.445

Review 8.  Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.

Authors:  Kelly J Lafaro; David Cosgrove; Jean-Francois H Geschwind; Ihab Kamel; Joseph M Herman; Timothy M Pawlik
Journal:  Gastroenterol Res Pract       Date:  2015-05-19       Impact factor: 2.260

9.  Predictors and patterns of recurrence after curative liver resection in intrahepatic cholangiocarcinoma, for application of postoperative radiotherapy: a retrospective study.

Authors:  Eunmi Gil; Jae-Won Joh; Hee Chul Park; Jeong Il Yu; Sang Hoon Jung; Jong Man Kim
Journal:  World J Surg Oncol       Date:  2015-07-29       Impact factor: 2.754

10.  Intraoperative Conversion to ALPPS in a Case of Intrahepatic Cholangiocarcinoma.

Authors:  F Oldhafer; K I Ringe; K Timrott; M Kleine; W Ramackers; S Cammann; M D Jäger; J Klempnauer; H Bektas; F W R Vondran
Journal:  Case Rep Surg       Date:  2015-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.